Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Tretinoin may help cells that are involved in the body's immune response to work better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving tretinoin together with interleukin-2 may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well giving three different doses of tretinoin together with interleukin-2 works in treating patients with stage IV kidney cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
OBJECTIVES:
Primary
-
Determine the ratio of dendritic cells (DC) to circulating immature cells (ImC) before and after treatment with 3 different doses of tretinoin in patients with stage IV renal cell cancer.
-
Assess in vitro immune response assays to tetanus toxoid and influenza virus peptide before and after treatment with tretinoin and interleukin-2 in these patients.
Secondary
-
Determine the frequency of treatment-related side effects in these patients.
-
Determine clinical objective response and progression-free survival of patients treated with this regimen.
-
Correlate DC:ImC ratio with clinical objective response in patients treated with this regimen.
-
Correlate the extent of change of the DC:ImC ratio with tretinoin dose and tretinoin blood levels in these patients.
OUTLINE: This is a randomized, open-label study. Specimens are stratified according to patient prognostic factors, tumor bulk, and extent of dendritic cell to circulating immature cell ratio derangement. Patients are randomized to 1 of 3 tretinoin doses.
Patients are followed for up to 2 years.
PROJECTED ACCRUAL: A total of 27-36 patients (9-12 per treatment arm) will be accrued for this study within 2 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: ATRA Followed by IL-2 - Dose Level A Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment. Week 1: One dose daily of IL-2 for 5 days followed by 2 days off. Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off. After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule. This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle. |
Drug: IL-2
Immunotherapy with interleukin-2
Other Names:
Drug: ATRA
Other Names:
|
| Active Comparator: ATRA Followed by IL-2 - Dose Level B Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment. Week 1: One dose daily of IL-2 for 5 days followed by 2 days off. Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off. After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule. This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle. |
Drug: IL-2
Immunotherapy with interleukin-2
Other Names:
Drug: ATRA
Other Names:
|
| Active Comparator: ATRA Followed by IL-2 - Level C Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment. Week 1: One dose daily of IL-2 for 5 days followed by 2 days off. Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off. After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule. This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle. |
Drug: IL-2
Immunotherapy with interleukin-2
Other Names:
Drug: ATRA
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Ratio of Dendritic Cells (DC) to Circulating Immature Cells (ImC) Before and After Treatment [1 year, 3 months]
Determine the ratio of dendritic cells (DC) to circulating immature cells (ImC) before and after treatment with 3 different doses of tretinoin in patients with stage IV renal cell cancer.
Secondary Outcome Measures
- Frequency of Treatment-Related Side Effects [1 year, 3 months]
Review of adverse events utilizing Common Toxicity Criteria (CTC) V3.
- Overall Response Rate (ORR) [1 year, 3 months]
Objective Response Rate according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Evaluate per-patient observed best clinical responses, after 11-12 weeks of treatment.
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed renal cell cancer
-
Stage IV disease
-
Histology with clear cell component
-
Metastatic OR incompletely resected disease
-
Non-measurable disease allowed
-
Underwent complete or partial nephrectomy more than 90 days ago
-
No unresected primary cancer
-
No more than 2 of the following adverse factors:
-
Hemoglobin < 10.0 g/dL
-
Corrected calcium > upper limit of normal (ULN)
-
Lactic dehydrogenase > 1.5 times ULN
-
Eastern Cooperative Oncology Group (ECOG) performance status 2
-
Brain metastasis allowed provided more than 90 days of clinical and radiologic stability after the end of its active treatment
PATIENT CHARACTERISTICS:
Age
- Over 18
Performance status
-
See Disease Characteristics
-
ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- See Disease Characteristics
Hepatic
-
See Disease Characteristics
-
Serum glutamic oxaloacetic transaminase (SGOT) < 3 times normal
-
Bilirubin < 2 times normal
Renal
-
See Disease Characteristics
-
Creatinine clearance > 40 mL/min
Cardiovascular
-
None of the following cardiovascular conditions within the past year:
-
Uncontrolled hypertension
-
Myocardial infarction
-
Unstable angina
-
New York Heart Association class II-IV congestive heart failure
-
Serious cardiac arrhythmia requiring medication
-
Class II-IV peripheral vascular disease within the past year
-
Other clinically significant cardiovascular disease
Immunologic
-
No history of immunodeficiency disease
-
No HIV infection
-
No ongoing serious infection
Other
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use two methods of effective contraception during and for 1 month (for women) or 6 months (for men) after study treatment
-
Other prior malignancy allowed provided there is no evidence of active disease
-
No other medical contraindication to tretinoin or interleukin-2
-
No serious non-healing wound, ulcer, or bone fracture
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 60 days since prior immunotherapy
Chemotherapy
- At least 60 days since prior cytotoxic chemotherapy
Endocrine therapy
-
See Radiotherapy
-
No prior corticosteroids at > physiologic replacement doses for > 3 days within the past 90 days
-
Concurrent tamoxifen, toremifene, megestrol, or gonadotropin-releasing hormone agonists allowed
-
Concurrent inhaled steroids allowed
Radiotherapy
-
More than 7 days since prior external-beam radiotherapy
-
No steroid requirement during radiotherapy
Surgery
-
See Disease Characteristics
-
At least 30 days since other prior debulking surgery
Other
-
Prior adjuvant therapy for resected, synchronous stage IV disease allowed
-
Prior adjuvant therapy allowed
-
Study therapy is not to be used as adjuvant therapy for completely resected late (> 1 year until identification) solitary site of disease metastasis or non-metastatic disease
-
No prior participation in this clinical study
-
At least 60 days since other prior anticancer drugs
-
Concurrent seizure medication allowed
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | United States | 33612-9497 |
Sponsors and Collaborators
- H. Lee Moffitt Cancer Center and Research Institute
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- Chiron Corporation
Investigators
- Principal Investigator: Mayer Fishman, M.D., Ph.D., H. Lee Moffitt Cancer Center and Research Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MCC-13920
- CA101324
- CA84488